Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: A randomised, double-blind, phase III equivalence study

1. Cohen, S.
2. Genovese, M.C.
3. Choy, E.
4. Perez-Ruiz, F.
5. Matsumoto, A.
6. Pavelka, K.
7. Pablos, J.L.
8. Rizzo, W.
9. Hrycaj, P.
10. Zhang, N.
11. Shergy, W.
12. Kaur, P.